


Earliest available Table of Contents:  
 Automatically, free of charge by e-mail through  
[www.interscience.wiley.com/alerts](http://www.interscience.wiley.com/alerts)

## COVER PICTURE

**The cover picture shows** an organoruthenium antimetastasis compound, superimposed over a Sudoku puzzle, representing the challenge of discovering new anticancer drugs and elucidating their mechanisms of action. One needs to uncover pieces of information which are interrelated, and eventually, the complete “picture” is revealed. In this review, we describe the extent to which the picture has been revealed for ruthenium-based drugs, which are currently growing in interest as a result of recent successes in clinical trials. The emphasis is directed towards classifying the vast array of ruthenium compounds already evaluated in vitro and in vivo against primary and secondary cancers within the context of their probable target. It is hoped that on the basis of the picture presented here more of this intriguing puzzle will be revealed soon. Details are presented in the Microreview by W. H. Ang and P. J. Dyson on p. 4003ff.



## MICROREVIEW

### Contents

### 4003 W. H. Ang, P. J. Dyson\*

Classical and Non-Classical Ruthenium-Based  
 Anticancer Drugs: Towards Targeted Chemo-  
 therapy

**Keywords:** Ruthenium / Anticancer drugs / Targeted  
 chemotherapy / DNA binding / Antimetastasis  
 drugs

